Compare MXCT & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | YARW |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 154.5M |
| IPO Year | 2021 | 2017 |
| Metric | MXCT | YARW |
|---|---|---|
| Price | $1.38 | $13.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.11 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 1.4M | 180.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $12.39 |
| 52 Week High | $1.80 | $44.28 |
| Indicator | MXCT | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 36.52 |
| Support Level | $1.02 | $12.39 |
| Resistance Level | $1.54 | $20.35 |
| Average True Range (ATR) | 0.14 | 2.62 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 70.41 | 18.38 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.